MIB-1 labelling index is an independent prognostic marker in primary breast cancer (Q36115384)

12 August 2017

MIB-1 labelling index is an independent prognostic marker in primary breast cancer (English)

1 reference

12 August 2017

1 reference

Jansen RL

1

1 reference

12 August 2017

Hupperets PS

2

1 reference

12 August 2017

Arends JW

3

1 reference

12 August 2017

Joosten-Achjanie SR

4

1 reference

12 August 2017

Volovics A

5

1 reference

12 August 2017

Schouten HC

6

1 reference

12 August 2017

Hillen HF

7

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 1998

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

78

1 reference

12 August 2017

460-465

1 reference

12 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.515

12 August 2017

0 references

cites work

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

MIB-1 proliferative activity in invasive breast cancer measured by image analysis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Flow cytometry using paraffin-embedded tissue: five years on.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Ki67 immunostaining in primary breast cancer: pathological and clinical associations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063089

Is routine axillary nodal dissection necessary in the treatment of breast cancer?

23 September 2018

1 reference

12 December 2020

The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer

1 reference

12 December 2020

Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue

1 reference

12 December 2020

Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor

1 reference

12 December 2020

Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67

1 reference

12 December 2020

Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues

1 reference

12 December 2020

Proliferation index as a prognostic marker in breast cancer

1 reference

12 December 2020

Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry

1 reference

12 December 2020

Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis

1 reference

12 December 2020

Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer

1 reference

12 December 2020

Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up

1 reference

12 December 2020

Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1

1 reference

12 December 2020

Estimation of the proliferative activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies--comparative studies on frozen and paraffin sections

1 reference

12 December 2020

Expression of pS2 estrogen-inducible protein in primary breast cancer

1 reference

12 December 2020

Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.515

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference

12 August 2017

1 reference